2022 systematic review of 83 trials.
Walsh, Zach, et al. “Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.” BJPsych Open 8.1 (2022).
2021 review of neurobiological mechanisms.
Kohtala, Samuel. “Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms.” Pharmacological Reports (2021): 1-23.
2020 safety review of 6630 patients.
Feifel, David, David Dadiomov, and Kelly C Lee. “Safety of repeated administration of parenteral ketamine for depression.” Pharmaceuticals 13.7 (2020): 151.
2018 blood pressure safety review.
Riva-Posse, Patricio, et al. “Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions.” Journal of affective disorders 236 (2018): 291-297.
2018 blood pressure safety review.
Riva-Posse, Patricio, et al. “Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions.” Journal of affective disorders 236 (2018): 291-297.
2017 review on ethics and safety.
Singh, I., Morgan, C., Curran, V., Nutt, D., Schlag, A., & McShane, R. (2017). Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. The Lancet Psychiatry, 4(5), 419-426.
2016 safety and efficacy review.
Kishimoto, T., et al. “Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.” Psychological medicine 46.7 (2016): 1459-1472.
2014 safety review.
Wan, Le-Ben, et al. “Ketamine safety and tolerability in clinical trials for treatment-resistant depression.” The Journal of clinical psychiatry 76.3 (2014): 0-0.
2010 safety review.
Aan Het Rot, Marije, et al. “Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.” Biological psychiatry 67.2 (2010): 139-145.
2022 on combining ACT therapy with ketamine.
Mathai, D. S., Mora, V., & Garcia-Romeu, A. (2022). Toward Synergies of Ketamine and Psychotherapy. Frontiers in Psychology, 1203.
2022 systematic narrative review of ketamine-assisted psychotherapy.
Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J., Ritvo, P., Mattina, G. F., … & Ladha, K. S. (2022). Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of Pain Research, 15, 1691.
2022 therapy augments effects of ketamine for alcohol use disorder.
Grabski, M., McAndrew, A., Lawn, W., Marsh, B., Raymen, L., Stevens, T., … & Morgan, C. J. A. (2022). Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. The American Journal of Psychiatry, appiajp202121030277-appiajp202121030277.
2022 optimizing ketamine treatment with trauma-informed psychotherapy.
Muscat, S. A., Hartelius, G., Crouch, C. R., & Morin, K. W. (2022). Optimized Clinical Strategies for Treatment-Resistant Depression: Integrating Ketamine Protocols with Trauma-and Attachment-Informed Psychotherapy. Psych, 4(1), 119-141.
2021 therapy enhances durability of treatment effect.
Wilkinson, Samuel T., et al. “Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial.” Psychotherapy and psychosomatics 90.5 (2021): 318-327.
2020 review of therapeutic mechanisms to augment effect.
Greenway, Kyle T., et al. “Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.” Expert Review of Clinical Pharmacology 13.6 (2020): 655-670.
2020 editorial on Motivational Enhancement Therapy to augment effect.
Mathew, Sanjay J., and Rebecca B. Price. “Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change.” American Journal of Psychiatry 177.2 (2020): 107-109.
2020 review of psychotherapeutic mechanisms to augment effect.
Hasler, Gregor. “Toward specific ways to combine ketamine and psychotherapy in treating depression.” CNS spectrums 25.3 (2020): 445-447.
2020 ketamine combined with motivational enhancement therapy for alcohol use disorder.
Dakwar, Elias, et al. “A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial.” American Journal of Psychiatry 177.2 (2020): 125-133.
2019 data from KAP clinics.
Dore, Jennifer, et al. “Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy.” Journal of psychoactive drugs 51.2 (2019): 189-198.
2019 mindfulness-based therapy enhances positive effects with cocaine dependence.
Dakwar, Elias, et al. “A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial.” American Journal of Psychiatry 176.11 (2019): 923-930.
2021 narrative review of ketamine for depression.
Jelen, Luke A., and James M. Stone. “Ketamine for depression.” International Review of Psychiatry 33.3 (2021): 207-228.
2021 international expert opinion.
McIntyre, Roger S., et al. “Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation.” American Journal of Psychiatry 178.5 (2021): 383-399.
2021 systematic review of 83 trials.
Walsh, Zach, et al. “Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.” BJPsych Open 8.1 (2022).
2021 Canadian task force recommendations.
Swainson, Jennifer, et al. “The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder: Recommandations du groupe de travail du réseau canadien pour les traitements de l’humeur et de l’anxiété (canmat) concernant l’utilisation de la kétamine racémique chez les adultes souffrant de trouble dépressif majeur.” The Canadian Journal of Psychiatry 66.2 (2021): 113-125.
2021 systematic review and meta-analysis.
Bahji, Anees, Gustavo H. Vazquez, and Carlos A. Zarate Jr. “Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.” Journal of affective disorders 278 (2021): 542-555.
2021 brief summary review in the Journal of the Norwegian Medical Association.
Kvam, T. M., Stewart, L. H., Blomkvist, A. W., & Andreassen, O. A. (2021). Ketamine for depression–evidence and proposals for practice. Tidsskrift for Den norske legeforening.
Krystal, John H., et al. “Ketamine: a paradigm shift for depression research and treatment.” Neuron 101.5 (2019): 774-778.
2017 CBT plus ketamine for depression.
Wilkinson, Samuel T., et al. “Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression.” Psychotherapy and psychosomatics 86.3 (2017): 162-167.
2017 consensus from the American Psychiatric Association.
Sanacora, Gerard, et al. “A consensus statement on the use of ketamine in the treatment of mood disorders.” JAMA psychiatry 74.4 (2017): 399-405.
2013 trial demonstrating increased durability by repeat treatments.
Murrough, James W., et al. “Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.” Biological psychiatry 74.4 (2013): 250-256.
2021 systematic review.
Hochschild, Annabella, Michael F. Grunebaum, and J. John Mann. “The rapid anti-suicidal ideation effect of ketamine: a systematic review.” Preventive medicine 152 (2021): 106524.
2020 systematic review and meta-analysis.
Witt, Katrina, et al. “Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials.” Australian & New Zealand Journal of Psychiatry 54.1 (2020): 29-45.
2018 systematic review and meta-analysis.
Wilkinson, Samuel T., et al. “The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis.” American journal of psychiatry 175.2 (2018): 150-158.
2018 large RCT.
Grunebaum, Michael F., et al. “Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial.” American Journal of Psychiatry 175.4 (2018): 327-335.
2022 KARE study for alcohol use disorder.
Grabski, M., et al. “Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder.” The American Journal of Psychiatry (2022)
Key results: 87% abstinence, significantly higher than placebo. 2.5x more likely to stay abstinent at 6 months compared to those on placebo.
2022 systematic review of 83 trials.
Walsh, Zach, et al. “Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.” BJPsych Open 8.1 (2022).
2021 review for alcohol use disorder.
Worrell, Stephen D., and Thomas J. Gould. “Therapeutic Potential of Ketamine for Alcohol Use Disorder.” Neuroscience & Biobehavioral Reviews (2021).
2021 review for addiction, OCD and eating disorders.
Martinotti, Giovanni, et al. “Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.” Brain Sciences 11.7 (2021): 856.
2021 ketamine for cannabis use disorder.
Azhari, Nour, et al. “Ketamine-facilitated behavioral treatment for cannabis use disorder: a proof of concept study.” The American journal of drug and alcohol abuse 47.1 (2021): 92-97.
2020 mechanisms for ketamine for alcohol use disorder.
Strong, Caroline E., and Mohamed Kabbaj. “Neural Mechanisms Underlying the Rewarding and Therapeutic Effects of Ketamine as a Treatment for Alcohol Use Disorder.” Frontiers in Behavioral Neuroscience 14 (2020): 225.
2020 ketamine plus motivational therapy for alcohol use disorder.
Dakwar, Elias, et al. “A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial.” American Journal of Psychiatry 177.2 (2020): 125-133.
2019 RCT for cocaine dependence.
Dakwar, Elias, et al. “A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial.” American Journal of Psychiatry 176.11 (2019): 923-930.
2019 RCT for cocaine use disorder.
Dakwar, E., et al. “Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial.” Molecular psychiatry 22.1 (2017): 76-81.
2019 ketamine for alcohol use disorder.
Das, Ravi K., et al. “Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories.” Nature communications 10.1 (2019): 1-10.
2018 review of ketamine for substance use disorders.
Ezquerra-Romano, I. Ivan, et al. “Ketamine for the treatment of addiction: Evidence and potential mechanisms.” Neuropharmacology 142 (2018): 72-82.
2018 systematic review of ketamine for substance use disorders.
Jones, Jennifer L., et al. “Efficacy of ketamine in the treatment of substance use disorders: a systematic review.” Frontiers in psychiatry 9 (2018): 277.
2017 review for substance use disorders.
Morgan, Celia, et al. “Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use.” Current Opinion in Behavioral Sciences 13 (2017): 71-76.
2007 ketamine for heroin dependence.
Krupitsky, Evgeny M., et al. “Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence.” Journal of psychoactive drugs 39.1 (2007): 13-19.
2002 ketamine for heroin addiction.
Krupitsky, Evgeny, et al. “Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.” Journal of substance abuse treatment 23.4 (2002): 273-283.
Feder, Adriana, et al. “A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder.” American Journal of Psychiatry 178.2 (2021): 193-202.
2021 review of ketamine for PTSD and putative mechanisms.
Asim, Muhammad, et al. “Ketamine For Post-Traumatic Stress Disorders And It’s Possible Therapeutic Mechanism.” Neurochemistry International (2021): 105044.
2021 review for addiction, OCD and eating disorders.
Martinotti, Giovanni, et al. “Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.” Brain Sciences 11.7 (2021): 856.
2020 review for the treatment of anxiety disorders.
Banov, Michael D., et al. “Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature.” CNS spectrums 25.3 (2020): 331-342.
2020 review of ketamine for PTSD
Feder, Adriana, et al. “The emergence of ketamine as a novel treatment for posttraumatic stress disorder.” Advances in Pharmacology 89 (2020): 261-286.
2020 review for the treatment of OCD.
Sharma, Lavanya P., et al. “Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder.” Asian journal of psychiatry 52 (2020): 102183.
2019 ketamine for PTSD in combat veterans.
Ross, Cassie, et al. “High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans.” Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists 31.4 (2019): 271-279.
2018 RCT for social anxiety disorder.
Taylor, Jerome H., et al. “Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial.” Neuropsychopharmacology 43.2 (2018): 325-333.
2018 ketamine with psychotherapy in trauma.
Veen, Cato, et al. “Subanesthetic dose ketamine in posttraumatic stress disorder: a role for reconsolidation during trauma-focused psychotherapy?.” Behavioral neurobiology of PTSD. Springer, Cham, 2018. 137-162.
2017 ketamine for treatment resistant anxiety disorders.
Glue, Paul, et al. “Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.” Journal of Psychopharmacology 31.10 (2017): 1302-1305.
2014 first RCT of ketamine for chronic PTSD.
Feder, Adriana, et al. “Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.” JAMA psychiatry 71.6 (2014): 681-688.
2013 first RCT with ketamine for OCD.
Rodriguez, Carolyn I., et al. “Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.” Neuropsychopharmacology 38.12 (2013): 2475-2483.
2021 review of ketamine for anorexia.
Keeler, Johanna Louise, et al. “Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review.” Nutrients 13.11 (2021): 4158.
Schwartz, Terry, et al. “A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression.” Clinical case reports 9.5 (2021): e03869.
Enter your details in the form below to discover a unique path to healing your mental health, proven effective where other treatments have failed.
